What is William Blair’s Estimate for Alector Q1 Earnings?

Alector, Inc. (NASDAQ:ALEC) – Equities research analysts at William Blair issued their Q1 2026 EPS estimates for shares of Alector in a report issued on Thursday, February 27th. William Blair analyst M. Minter forecasts that the company will post earnings of ($0.54) per share for the quarter. The consensus estimate for Alector’s current full-year earnings is ($1.88) per share. William Blair also issued estimates for Alector’s Q2 2026 earnings at ($0.53) EPS, Q3 2026 earnings at ($0.54) EPS and Q4 2026 earnings at ($0.52) EPS.

ALEC has been the topic of a number of other reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Alector in a report on Tuesday, November 26th. Stifel Nicolaus downgraded shares of Alector from a “buy” rating to a “hold” rating and set a $4.00 price target on the stock. in a research note on Monday, December 16th. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price objective on shares of Alector in a research note on Thursday. Bank of America lowered shares of Alector from a “neutral” rating to an “underperform” rating and reduced their target price for the company from $9.00 to $1.00 in a report on Wednesday, December 4th. Finally, Morgan Stanley downgraded shares of Alector from an “equal weight” rating to an “underweight” rating and lowered their price target for the stock from $10.00 to $3.00 in a research note on Tuesday, November 26th. Two analysts have rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $3.75.

Alector Stock Down 1.2 %

Shares of ALEC stock opened at $1.64 on Friday. The business has a 50-day moving average price of $1.78 and a two-hundred day moving average price of $3.53. Alector has a 12-month low of $1.55 and a 12-month high of $7.57. The firm has a market cap of $160.61 million, a P/E ratio of -0.96 and a beta of 0.61.

Alector (NASDAQ:ALEC) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.59. The company had revenue of $54.24 million during the quarter, compared to the consensus estimate of $20.41 million. Alector had a negative net margin of 257.54% and a negative return on equity of 108.77%.

Insider Activity at Alector

In related news, insider Sara Kenkare-Mitra sold 26,500 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $2.52, for a total value of $66,780.00. Following the sale, the insider now directly owns 565,215 shares of the company’s stock, valued at $1,424,341.80. This trade represents a 4.48 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Arnon Rosenthal sold 52,172 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $2.52, for a total value of $131,473.44. Following the transaction, the chief executive officer now directly owns 2,507,074 shares of the company’s stock, valued at $6,317,826.48. The trade was a 2.04 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 95,161 shares of company stock worth $239,806 in the last three months. 9.10% of the stock is owned by insiders.

Institutional Trading of Alector

Several large investors have recently added to or reduced their stakes in the stock. Creative Planning boosted its stake in shares of Alector by 54.2% during the 3rd quarter. Creative Planning now owns 19,117 shares of the company’s stock valued at $89,000 after purchasing an additional 6,723 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in Alector by 65.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 18,718 shares of the company’s stock worth $87,000 after buying an additional 7,395 shares during the period. Victory Capital Management Inc. boosted its position in Alector by 19.5% during the 3rd quarter. Victory Capital Management Inc. now owns 186,747 shares of the company’s stock valued at $870,000 after acquiring an additional 30,513 shares in the last quarter. Intech Investment Management LLC purchased a new position in shares of Alector during the 3rd quarter worth approximately $90,000. Finally, Massachusetts Financial Services Co. MA raised its position in shares of Alector by 54.7% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 174,718 shares of the company’s stock worth $814,000 after acquiring an additional 61,798 shares in the last quarter. Institutional investors own 85.83% of the company’s stock.

Alector Company Profile

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.